Optas LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

Optas LLC’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$216K	Sell	347 -15	-4%	-$10.2K	0.03%	430
2026 Q1	$280K	Sell	362 -3	-0.8%	-$2.3K	0.04%	335
2025 Q4	$282K	Buy	+365	New	+$248K	0.04%	323
2021 Q3	–	Sell	-961	Closed	-$537K	–	154
2021 Q2	$537K	Buy	961 +5	+0.5%	+$2.53K	0.15%	87
2021 Q1	$452K	Buy	956 +476	+99%	+$232K	0.14%	91
2020 Q4	$232K	Sell	480 -447	-48%	-$241K	0.07%	123
2020 Q3	$519K	Buy	927 +344	+59%	+$209K	0.16%	92
2020 Q2	$363K	Sell	583 -236	-29%	-$134K	0.15%	81
2020 Q1	$400K	Buy	+819	New	+$338K	0.2%	69

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

Optas LLC's REGN Position: Q2 2026 in Review

Optas LLC reduced its Regeneron Pharmaceuticals (REGN) stake by 4.1% in Q2 2026, selling an estimated $10.2K and leaving 347 shares worth $216K. The position accounts for 0.03% of the portfolio, ranked #430.

Optas LLC first reported a position in REGN in Q1 2020 and has held it in 9 quarters since. The position peaked at $537K in Q2 2021. 310 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Optas LLC held 347 shares of Regeneron Pharmaceuticals worth $216K as of Q2 2026.
Optas LLC sold 15 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $10.2K.
Regeneron Pharmaceuticals made up 0.03% of Optas LLC's portfolio in Q2 2026, its #430 holding.
Optas LLC first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 9 quarters since.
Optas LLC's Regeneron Pharmaceuticals position peaked at $537K in Q2 2021.
310 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Optas LLC's 13F filing for Q2 2026, filed 21 Jul 2026.